The article focuses on the treatment of cutaneous lupus erythematosus. It mentions that Belimumab is a B-lymphocyte stimulator–specific inhibitor that was first approved for treatment of systemic lupus erythematosus. It also informs that Baricitinib is a selective and reversible inhibitor of JAK1 and JAK2 that was granted fast-track status by the Food and Drug Administration.